1468results about "Recombinant DNA-technology" patented technology

Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, oligonucleotides comprise various chemical modifications. In some embodiments, the present disclosure provides technologies useful for manufacturing oligonucleotides.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

An improved method of treating cancers with engineered T cells is described.

Analyze gene mutations including missense mutations and / or nonsense mutations and silent mutations with high precision. 【Solution means】Detect signals from a first probe corresponding to a missense mutation or nonsense mutation in a gene mutation, a second probe corresponding to a silent mutation in the gene mutation, and a wild-type probe corresponding to the wild type, and determine the signal from the second probe as the wild type in the gene mutation.

To provide a method, a composition, and a kit for predicting the onset of moyamoya disease in a subject carrying a genetic mutation responsible for moyamoya disease.SOLUTION: Disclosed herein is a method for predicting the onset of moyamoya disease, the method including measuring the expression level of GATA2 in a sample derived from a subject carrying the p.R4810K mutation in the RNF213 gene. Also disclosed is a composition or a kit for predicting the onset of moyamoya disease in a subject carrying the p.R4810K mutation in the RNF213 gene, the composition or kit including a reagent for measuring the expression level of GATA2.SELECTED DRAWING: None

The present invention relates to a novel process for preparing compounds of formula (I) and pharmaceutically acceptable salts thereof which act as ferroportin inhibitors suitable for use as pharmaceuticals in the prevention and / or treatment of diseases caused by a deficiency of hepcidin or of disorders of iron metabolism leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis. JPEG2023533889000140.jpg34103

Disclosed herein are methods, compositions, and devices for use in early detection of cancer. The methods include sequencing a panel of regions in cell-free nucleic acid molecules and detecting one or more tumor markers that are indicative of a cancer.

The invention provides a method of inducing a DNA-encoded library (DEL) comprising cleavable site(s) in the DNA strand to a cross linker-modified double-stranded DEL and evaluating the DEL. Both the merits of the hairpin-stranded DEL and the double-stranded DEL are achieved in the invention by introducing the cleavable site(s) such as deoxyuridine into the DNA strand. The invention further provides a technique for screening a compound in which both “simple DEL synthesis method” and “expansion and improvement of the DEL evaluation method” are achieved by easily inducing the compound into a cross linker-modified DEL.

Provided herein are methods for determining allele-specific telomere length (ATL) and telomere variant repeat (TVR) sequences from long read sequencing data. In some embodiments, the methods include clustering telomere reads together into individual alleles using their adjacent TVR regions from which allele-specific TL can then be determined.

The disclosure relates, inter alia, to a library of transcriptional data, and methods for assembling and using same.

To identify gene mutations in MYD88 and / or CD79B simultaneously.SOLUTION: The present invention comprises: a primer set for MYD88 gene mutations, and a primer set for CD79B gene mutations; as well as a mutant-type probe for MYD88 gene, a wild-type probe for MYD88 gene, a mutant-type probe for CD79B gene, and a wild-type probe for CD79B gene.SELECTED DRAWING: None

An anti-BDCA-2 antibody or an antigen-binding fragment thereof. Also provided are a composition comprising the anti-BDCA-2 antibody or the antigen-binding fragment thereof, a nucleic acid encoding the anti-BDCA-2 antibody or the antigen-binding fragment thereof, a vector comprising the nucleic acid, and a host cell. Also provided are a therapeutic use of the anti-BDCA-2 antibody or the antigen-binding fragment thereof and a pharmaceutical composition comprising same.

To provide methods of producing hexoses from saccharides by improved enzymatic processes.SOLUTION: Methods of producing hexoses from saccharides by improved enzymatic processes are disclosed herein. The improved processes utilize enzymes with higher activities than those previously reported to convert starch or a starch derivative, cellulose or a cellulose derivative, or sucrose to a glucose 6-phosphate (G6P) intermediate.SELECTED DRAWING: Figure 2

Provided is a cell culture substrate comprising a substrate and a layer that covers at least a portion of the surface of the substrate, has a layer thickness of 5 to 2000 nm and contains a hydrophilic polymer, in which the hydrophilic polymer contains a phosphorylcholine group or a hydroxyl group, the cell culture substrate has a region (A) and a region (B) as mentioned below, and the bump height in a boundary region between the region (A) and the region (B) is 1 to 500 nm. (A) An island-like region which has cell adhesiveness and cell proliferating properties and has an area of 0.001 to 5 mm2. (B) A region which is located adjacent to the region (A) and does not have cell adhesiveness or cell proliferating properties.

To provide methods of treating a human subject having non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), and in certain embodiments, NPD subtype B.SOLUTION: A method for treating a human subject having an acid sphingomyelinase deficiency comprises: (a) a regimen for debulking an accumulated sphingomyelin substrate in the human subject including (i) administering an initial low non-toxic dose of an acid sphingomyelinase (ASM) to the human subject, and (ii) administering successively higher doses of ASM to the human subject and monitoring the subject for one or more adverse side effects after each successive dose as indicated by elevated bilirubin or a related adverse event; and (b) a maintenance regimen comprising administering a dose equal to or less than the highest dose tolerated by the subject as a maintenance dose for the subject.SELECTED DRAWING: None

Described herein are serum-free and feeder-free methods and compositions for the tunable differentiation and production of CD4+ (single positive) T cells and CD8+ (single positive) T cells, by adjusting T cell receptor (TCR) stimulation and notch activation (or notch signaling activation, stimulation or inducement). In some other aspects the invention provides a method and in vitro niche and cell culture media that results in enhancing CD4+ (SP) T cell generation, including naive mature CD4+ single positive T cells from double positive (DP) CD4+8+cells or CD8+(SP) T cells by TCR stimulation while having low or no notch signaling activation, stimulation or inducement. In yet other aspects, the invention provides a method, niche and culture media for producing cells derived from CD4+ (SP) T cells, including Treg cells.

This invention provides antibodies or functional antibody fragments or probes thereof targeting a unique set of antigens recognized in cancer. The invention comprises a nucleotide sequence derived from the L2A5 monoclonal antibody. The antibodies or functional antibody fragments or probes thereof include variable heavy chain domains and variable light chain domains having the amino acid sequences provided herein. The DNA / amino acid sequence binding is unique and has never been previously described. The invention further provides antibodies or functional antibody fragments or conjugates or recombinant proteins useful for the detection, treatment, and prevention of human diseases, including cancer.

Provided are nucleic acid molecules encoding mutant Seneca Valley Virus (SVV) that evade neutralizing antibodies with a binding specificity to SVV, as well as nanoparticles containing rapamycin and SVV or mutant SVV. The mutant SVV comprise one or more mutations in one or more SVV epitopes that prevent binding of the mutant SVV to the neutralizing antibodies. The one or more mutations of the mutant SVV may be in one or more SVV epitopes. The epitopes may be inVP1, VP2, and / or VP3 subunits of SVV. Also provided are methods of producing and using the mutant SVV for treating cancer. Also provided are methods of treating a subject comprising administering to the subject the nanoparticles comprising SVV, or mutant SVV, and rapamycin. Also provided are methods of treating a subject comprising administering to the subject SVV or mutant SVV, and cyclophosphamide.

As regards the beneficial intestinal bacteria present in the intestines of each individual, to provide a method for screening, by a simple, safe in vitro test, probiotics and prebiotics that promote the proliferation of beneficial intestinal bacteria.　A screening method according to the present invention screens probiotics or prebiotics that promote the proliferation of beneficial intestinal bacteria present in the intestine of a subject or a test animal and comprises a step for adding a fecal sample collected from a subject or a test animal and a candidate probiotic or a candidate prebiotic to a liquid culture medium and culturing anaerobically, and a step for evaluating the state of proliferation of the beneficial intestinal bacteria in the liquid culture medium after anaerobic culture. The liquid culture medium used for anaerobic culture is prepared so that the concentration of the constituent components of the liquid culture medium is 1 / 3 to 1 / 6 of the concentration normally used in the culture of beneficial intestinal bacteria.

Provided is a pharmaceutical composition for treating and / or preventing renal cystic ciliopathy, the composition comprises a retinoic acid receptor (RAR) agonist.

To provide compositions, methods and kits for detecting Treponema pallidum.SOLUTION: Presented are oligonucleotide hybridization probes, primer sets, methods, reaction mixtures, and kits for detecting nucleic acids of Treponema pallidum, the causative agent of syphilis. Disclosed assays are both highly sensitive and specific for detection of T. pallidum nucleic acids. Nucleic acid sequences of T. pallidum can be detected at a level of 100% positivity using test samples having only 30 copies / ml of a model in vitro transcript. The presence of potentially cross-reacting non-target microorganisms does not negatively impact assay results.SELECTED DRAWING: Figure 1A

An improved method of treating cancers with engineered T cells is described.

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.

The present invention belongs to the field of plant genetics research, and particularly relates to gene functions for increasing plant biomass and seed yield. The present invention discloses the use of a gene that negatively regulates plant biomass and seed yield. This gene is the AT3G28990 gene whose nucleotide sequence is shown in SEQ ID NO: 1. By knocking out the AT3G28990 gene in plants, the biomass and seed yield of plants can be increased. Knocking out the AT3G28990 gene of Arabidopsis thaliana can effectively increase the biomass and yield of plants. This has important reference significance for the breeding of high-yield crops.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and / or therapeutic agent.

The technology described herein is directed to methods of generating CD4+CD8- single-positive T cells from CD4+CD8+ double positive T progenitor cells using differentiation in the presence of interleukin-7 (IL-7) and an anti-CD3 agent and in absence of Notch ligand and an anti-CD28 agent. Also described herein are CD4+CD8- single-positive T cells made by the methods described herein, which can be used for therapeutic applications.

Disclosed are bifunctional compounds (degraders) that target HAT EP300 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

To provide a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs.SOLUTION: A composition comprises rhGAA, wherein: 40% to 60% of N-glycan on the rhGAA are complex-type N-glycans; and each rhGAA molecule contains at least one bis-phosphorylated mannose-6-phosphate (bis-M6 P) glycan. A pharmaceutical composition comprising the composition and at least one pharmaceutically acceptable carrier or additive are also provided.SELECTED DRAWING: Figure 1A

This invention provides a system and method for capturing and detecting polynucleotide chains. [Solution] The method may include the step of labeling at least one subsequence within a polynucleotide chain to obtain a labeled polynucleotide chain having at least one label. The method may further include the step of supplying a polymer to the surface of a channel and causing the polymer to physically interact with the surface of the channel. The method may further include the step of supplying a sample containing a labeled polynucleotide chain to the channel, the step of applying an electric field to the labeled polynucleotide chain to promote a physical interaction between the labeled polynucleotide chain and the polymer on the surface of the channel and to capture the labeled polynucleotide chain on the surface of the channel, and the step of detecting at least one label within the labeled polynucleotide chain.

This invention relates to methods and compositions for detecting a polymorphism in a target nucleic acid sequence using isothermal nucleic acid amplification. More specifically, the present invention relates to using recombinase polymerase amplification (RPA) or Nicking and Extension Amplification Reaction (NEAR) to detect single nucleotide polymorphisms in a target nucleic acid sequence.